



FHL1 rabbit pAb

using specific immunogen. Dilution WB 1: 500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleu Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in heaplacenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripherablood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a le extent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage:Elevated levels during postnatal muscle growth.,disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in allelic to severe early-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopat		
Applications WB Gene Name FHL1 SLIM1 Protein Name FHL1 Immunogen Synthesized peptide derived from human FHL1 AA range: 66-116 Specificity This antibody detects endogenous levels of FHL1 at Human/Mouse/Rat Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatograph using specific immunogen. Dilution WB 1: 500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleu Cytoplasm. cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in hea placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, hymas and periphen blood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a le extent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Gevelopmental stage: Elevated levels during postnatal muscle growth, disease: Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to seve early-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to seve early-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to seve	Catalog No	BYab-12356
Applications WB Gene Name FHL1 SLIM1 Protein Name FHL1 Immunogen Synthesized peptide derived from human FHL1 AA range: 66-116 Specificity This antibody detects endogenous levels of FHL1 at Human/Mouse/Rat Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit,IgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatograph using specific immunogen. Dillution WB 1: 500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleu Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in hea placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, hymas and peripherablood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a le extent in heart, colon, prostate and small intestine, Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage: Elevated levels during postnatal muscle growth, disease: Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to seve early-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to seve	Isotype	IgG
Gene Name FHL1 SLIM1 Protein Name FHL1 Immunogen Synthesized peptide derived from human FHL1 AA range: 66-116 Specificity This antibody detects endogenous levels of FHL1 at Human/Mouse/Rat Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatograph using specific immunogen. Dilution WB 1: 500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleus (Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in hea placenta, ovary, prostate, testis, small intestine, colon and spleen. Expressol barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripher blood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a le extent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage: Elevated levels during postnatal muscle growth, disease	Reactivity	Human; Mouse;Rat
Protein Name FHL1 Immunogen Synthesized peptide derived from human FHL1 AA range: 66-116 Specificity This antibody detects endogenous levels of FHL1 at Human/Mouse/Rat Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatograph using specific immunogen. Dilution WB 1: 500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleus of Ifferentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in hear placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripher blood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a lesser extent in hear colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function Func	Applications	WB
Immunogen Synthesized peptide derived from human FHL1 AA range: 66-116 Specificity This antibody detects endogenous levels of FHL1 at Human/Mouse/Rat Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatograph using specific immunogen. Dilution WB 1: 500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleu Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in heaplacenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripherablood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a le extent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage: Elevated levels during postnatal muscle growth., disease: Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MMI:300717], disease: Defects to seve early-onset reduc	Gene Name	FHL1 SLIM1
Specificity This antibody detects endogenous levels of FHL1 at Human/Mouse/Rat Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatograph using specific immunogen. Dilution WB 1: 500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleus Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in hear placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripher lood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a leextent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage: Elevated levels during postnatal muscle growth., disease: Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease: Defects in allelic to seve early-onset reducing body myopathy (RBM) [MIM:300717], disease: Defects in allelic to seve early-onset reducing body myopathy (RB	Protein Name	FHL1
Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG The antibody was affinity-purified from rabbit serum by affinity-chromatograph using specific immunogen. Dilution WB 1: 500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleu Cytoplasm. cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in hear placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and periphen-blood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a lexent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage: Elevated levels during postnatal muscle growth, disease: Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to sever early-onset reducing body myopathy (RBM) [MIM:300717], disease: Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease: Defects in Educing body myopathy (R	Immunogen	Synthesized peptide derived from human FHL1 AA range: 66-116
Purification The antibody was affinity-purified from rabbit serum by affinity-chromatograph using specific immunogen. Dilution WB 1: 500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleu Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in heaplacenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and periphen blood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a lextent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage:Elevated levels during postnatal muscle growth., disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects is allelic to sewe early-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in feath.	Specificity	This antibody detects endogenous levels of FHL1 at Human/Mouse/Rat
Purification The antibody was affinity-purified from rabbit serum by affinity-chromatograph using specific immunogen. Dilution WB 1: 500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleus Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in hea placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripherablood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a le extent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage:Elevated levels during postnatal muscle growth, diseases:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in SHMI 300717],	Formulation	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
using specific immunogen. Dilution WB 1: 500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleu Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in heaplacenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripherablood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a le extent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage:Elevated levels during postnatal muscle growth., disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in allelic to severe early-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717], disease:Defects in the cause of X-linked childhood-onset reducing body myopa	Source	Polyclonal, Rabbit,IgG
Purity ≥90% Storage Stability -20°C/1 year Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleus Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in hear placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barrely detectable in brain, lung, liver, kidney, pancreas, thymus and peripherablood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a leextent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage:Elevated levels during postnatal muscle growth.,disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to severearly-onset reducing body myopathy (RBM) [MIM:300717].,disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717].,disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717].,disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717].,disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717].,disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717].,disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717].,disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717].,disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717].,disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717].	Purification	The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
Purity ≥90% Storage Stability -20°C/1 year Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleu Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in hear placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripherablood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a le extent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage: Elevated levels during postnatal muscle growth., disease: Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to seve early-onset reducing body myopathy (RBM) [MIM:300717]., disease: Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease: Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease: Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease: Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717].	Dilution	WB 1: 500-2000
Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleus Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in hear placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripherablood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a le extent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage:Elevated levels during postnatal muscle growth., disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to seve early-onset reducing body myopathy (RBM) [MIM:300717]., disease:Defects in testis in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease:Defects in testis in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease:Defects in testis in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717].	Concentration	1 mg/ml
Synonyms Observed Band Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleus Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in hear placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripherablood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a le extent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage:Elevated levels during postnatal muscle growth., disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to seve early-onset reducing body myopathy (RBM) [MIM:300717]., disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease:Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717].	Purity	≥90%
Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleus Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in hear placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and periphers blood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a le extent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage:Elevated levels during postnatal muscle growth., disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to severally-onset reducing body myopathy (RBM) [MIM:300717]., disease:Defects in page 1.	Storage Stability	-20°C/1 year
Cell Pathway [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm. Nucleus.; [Isoform 2]: Nucleus Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in heat placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripherablood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a leextent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage: Elevated levels during postnatal muscle growth., disease: Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to severally-onset reducing body myopathy (RBM) [MIM:300717]., disease: Defects in testis in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease: Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease: Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease: Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717]., disease: Defects in the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300717].	Synonyms	
Cytoplasm, cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. Tissue Specificity Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in hear placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripherablood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a leextent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage: Elevated levels during postnatal muscle growth., disease: Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to severally-onset reducing body myopathy (RBM) [MIM:300717]., disease: Defects in part of the placent in myoblasts but is cytosolic in differentiated myotubes.	Observed Band	
placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression barely detectable in brain, lung, liver, kidney, pancreas, thymus and periphera blood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a le extent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. Function developmental stage:Elevated levels during postnatal muscle growth.,disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to seve early-onset reducing body myopathy (RBM) [MIM:300717].,disease:Defects in	Cell Pathway	
growth.,disease:Dēfects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to seve early-onset reducing body myopathy (RBM) [MIM:300717].,disease:Defects i	Tissue Specificity	Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in heart, placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression is barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripheral blood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a lesser extent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle.
[MIM:300695]. Scapuloperoneal syndrome (SPS) was initially described more	Function	developmental stage:Elevated levels during postnatal muscle growth.,disease:Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (RBM) [MIM:300718]. This disorder is allelic to severe early-onset reducing body myopathy (RBM) [MIM:300717].,disease:Defects in FHL1 are the cause of X-linked dominant scapuloperoneal myopathy [MIM:300695]. Scapuloperoneal syndrome (SPS) was initially described more

Nanjing BYabscience technology Co.,Ltd

网址: www.njbybio.com 官方热线: 025-5229-8998 监督电话: 15950492658




国内优质抗体供应商 精准的 WB 检测服务 24H 在线服务,欢迎咨询



	than 120 years ago by Jules Broussard as 'une forme hereditaire d'atrophie musculaire progressive' beginning in the lower legs and affecting the shoulder region earlier and more severely than distal arm. The etiology of this condition remains unclear., disease: Defects in FHL1 are the cause of X-linked myopathy with postural muscle atrophy (XMPMA) [MIM:300696]. Myopathies are inherited muscle disorders characterized by weakness and atrophy of voluntary skeletal muscle, and
Background	This gene encodes a member of the four-and-a-half-LIM-only protein family. Family members contain two highly conserved, tandemly arranged, zinc finger domains with four highly conserved cysteines binding a zinc atom in each zinc finger. Expression of these family members occurs in a cell- and tissue-specific mode and these proteins are involved in many cellular processes. Mutations in this gene have been found in patients with Emery-Dreifuss muscular dystrophy. Multiple alternately spliced transcript variants which encode different protein isoforms have been described.[provided by RefSeq, Nov 2009],
matters needing attention	Avoid repeated freezing and thawing!
Usage suggestions	This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.

Products Images



Western blot analysis of lysates from PC-12 cells, primary antibody was diluted at 1:1000, 4° over night

Nanjing BYabscience technology Co.,Ltd

网址: www.njbybio.com 官方热线: 025-5229-8998 监督电话: 15950492658